BACKGROUND: The prostate is an androgen-regulated organ and polymorphisms in genes involved in testosterone synthesis, in particular, SRD5A2 (A49T and V89L variants), CYP17 (MspAI variant), and the AR (CAG, GGC repeats), represent candidate risk factors for prostate cancer incidence and aggressiveness. METHODS: We evaluated the relationship between these five polymorphisms and prostate cancer risk in a family-based case-control study (N = 920). Cases were diagnosed at major medical institutions in Cleveland Ohio, and Detroit Michigan, and their unaffected brothers were used as controls. Associations were investigated with regard to prostate cancer risk, and clinical characteristics at diagnosis (i.e., tumor stage/grade, age, family history). RESULTS: The SRD5A2 V89L variant was associated with an increased risk of prostate cancer (OR = 1.56, P = 0.02). This association was driven primarily by men diagnosed at an earlier age (OR = 2.35, P = 0.001), or with more aggressive disease (OR = 1.63, P = 0.06). None of the other variants exhibited noteworthy associations with disease. CONCLUSIONS: These findings suggest that the SRD5A2 V89L variant may influence risk of developing prostate cancer, especially among men with a younger age of diagnosis or more aggressive disease. Copyright 2003 Wiley-Liss, Inc.
BACKGROUND: The prostate is an androgen-regulated organ and polymorphisms in genes involved in testosterone synthesis, in particular, SRD5A2 (A49T and V89L variants), CYP17 (MspAI variant), and the AR (CAG, GGC repeats), represent candidate risk factors for prostate cancer incidence and aggressiveness. METHODS: We evaluated the relationship between these five polymorphisms and prostate cancer risk in a family-based case-control study (N = 920). Cases were diagnosed at major medical institutions in Cleveland Ohio, and Detroit Michigan, and their unaffected brothers were used as controls. Associations were investigated with regard to prostate cancer risk, and clinical characteristics at diagnosis (i.e., tumor stage/grade, age, family history). RESULTS: The SRD5A2V89L variant was associated with an increased risk of prostate cancer (OR = 1.56, P = 0.02). This association was driven primarily by men diagnosed at an earlier age (OR = 2.35, P = 0.001), or with more aggressive disease (OR = 1.63, P = 0.06). None of the other variants exhibited noteworthy associations with disease. CONCLUSIONS: These findings suggest that the SRD5A2V89L variant may influence risk of developing prostate cancer, especially among men with a younger age of diagnosis or more aggressive disease. Copyright 2003 Wiley-Liss, Inc.
Authors: Akinobu Hamada; Romano Danesi; Douglas K Price; Tristan Sissung; Cindy Chau; David Venzon; Alex Sparreboom; William L Dahut; William D Figg Journal: Urology Date: 2007-08 Impact factor: 2.649
Authors: C Leigh Pearce; David J Van Den Berg; Nick Makridakis; Juergen K V Reichardt; Ronald K Ross; Malcolm C Pike; Laurence N Kolonel; Brian E Henderson Journal: Hum Mol Genet Date: 2008-05-10 Impact factor: 6.150
Authors: M Rahimi; M Ghanbari; Z Fazeli; M Rouzrokh; S Omrani; R Mirfakhraie; M D Omrani Journal: J Endocrinol Invest Date: 2016-11-15 Impact factor: 4.256
Authors: Matthew L Freedman; Celeste L Pearce; Kathryn L Penney; Joel N Hirschhorn; Laurence N Kolonel; Brian E Henderson; David Altshuler Journal: Am J Hum Genet Date: 2004-11-29 Impact factor: 11.025
Authors: Christine Neslund-Dudas; Cathryn H Bock; Kristin Monaghan; Nora L Nock; James J Yang; Andrew Rundle; Deliang Tang; Benjamin A Rybicki Journal: Prostate Date: 2007-11-01 Impact factor: 4.104